Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Update

Portage Biotech Inc. (NASDAQ:PRTG) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 47,400 shares, a growth of 558.3% from the August 15th total of 7,200 shares. Based on an average trading volume of 914,500 shares, the days-to-cover ratio is currently 0.1 days. Currently, 11.2% of the shares of the company are sold short.

Portage Biotech Stock Performance

NASDAQ:PRTG traded up $0.04 during trading hours on Friday, reaching $3.56. The stock had a trading volume of 43,349 shares, compared to its average volume of 342,447. The stock has a 50 day simple moving average of $3.56 and a 200 day simple moving average of $5.93. Portage Biotech has a 12-month low of $2.10 and a 12-month high of $60.00. The stock has a market cap of $3.74 million, a P/E ratio of -0.43 and a beta of 1.48.

Portage Biotech (NASDAQ:PRTG) last released its earnings results on Thursday, August 15th. The company reported ($24.20) earnings per share (EPS) for the quarter. On average, equities analysts expect that Portage Biotech will post -13 earnings per share for the current fiscal year.

Institutional Trading of Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Sanctuary Advisors LLC purchased a new position in Portage Biotech Inc. (NASDAQ:PRTG) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 297,728 shares of the company’s stock, valued at approximately $63,000. Sanctuary Advisors LLC owned 28.36% of Portage Biotech at the end of the most recent reporting period. 13.36% of the stock is owned by hedge funds and other institutional investors.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.